Try

Alto Neuroscience, Inc.

ANROUnited States

10 filed reports · 222 financial concepts · 0 earnings calls · 0 media appearances

Filed reports

10 reports · Mar 2024 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR81,166Mar 2024 to Jun 2026
Annual · 10-KSEC EDGAR2804Dec 2024 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 12, 2026254Open
FY2026 Q110-QMar 31, 2026May 13, 2026159Open
FY202510-KDec 31, 2025Mar 16, 2026509Open
FY2025 Q310-QSep 30, 2025Nov 12, 2025198Open
FY2025 Q210-QJun 30, 2025Aug 13, 2025100Open
FY2025 Q110-QMar 31, 2025May 14, 2025111Open
FY202410-KDec 31, 2024Mar 20, 2025295Open
FY2024 Q310-QSep 30, 2024Nov 12, 2024147Open
FY2024 Q210-QJun 30, 2024Aug 13, 202497Open
FY2024 Q110-QMar 31, 2024May 14, 2024100Open

Financial data

222 concepts · 1,970 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial215 concepts · 1,841 facts · Dec 2022 to Jun 2026

  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value17 · Mar 2023 to Jun 2026
  • Allocated share based compensation expense17 · Mar 2023 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents17 · Mar 2023 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect17 · Mar 2023 to Jun 2026
  • Common stock par or stated value per share17 · Mar 2023 to Jun 2026
  • Effect of exchange rate on cash cash equivalents restricted cash and restricted cash equivalents17 · Mar 2023 to Jun 2026
  • Fair value adjustment of warrants17 · Mar 2023 to Jun 2026
  • General and administrative expense (US GAAP)17 · Mar 2023 to Jun 2026
  • Increase decrease in accounts payable17 · Mar 2023 to Jun 2026
  • Increase decrease in accrued liabilities and other operating liabilities17 · Mar 2023 to Jun 2026
  • Increase decrease in prepaid deferred expense and other assets17 · Mar 2023 to Jun 2026
  • Interest expense nonoperating17 · Mar 2023 to Jun 2026
  • Interest paid net17 · Mar 2023 to Jun 2026
  • Investment income interest17 · Mar 2023 to Jun 2026
  • Net cash provided by used in financing activities17 · Mar 2023 to Jun 2026
  • Net cash provided by used in investing activities17 · Mar 2023 to Jun 2026
  • Net cash provided by used in operating activities17 · Mar 2023 to Jun 2026
  • Net income loss17 · Mar 2023 to Jun 2026
  • Non-cash interest expense related to term loan17 · Mar 2023 to Jun 2026
  • Nonoperating income expense17 · Mar 2023 to Jun 2026
  • Operating expenses (US GAAP)17 · Mar 2023 to Jun 2026
  • Operating income loss17 · Mar 2023 to Jun 2026
  • Operating lease right of use asset amortization expense17 · Mar 2023 to Jun 2026
  • Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent17 · Mar 2023 to Jun 2026

Segment6 concepts · 128 facts · Dec 2023 to Jun 2026

  • Research and development expense63 · Dec 2023 to Jun 2026
  • Allocated share based compensation expense13 · Dec 2023 to Jun 2026
  • Labor and related expense13 · Dec 2023 to Jun 2026
  • Net income loss13 · Dec 2023 to Jun 2026
  • Other general and administrative expense13 · Dec 2023 to Jun 2026
  • Other research and development expense13 · Dec 2023 to Jun 2026

Geography1 concepts · 1 facts · Dec 2024

  • Operating lease payments1 · Dec 2024

Segments

129 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments1 member · 128 facts

  • Reportable128 · Dec 2023 to Jun 2026

Statement geographical1 member · 1 facts

  • Los Altos California1 · Dec 2024

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Alto Neuroscience, Inc. (ANRO) data · FactIQ